New Study Challenges Long COVID Inflammation Theory
A recent brain imaging study is raising eyebrows about a commonly discussed cause of long COVID. Researchers discovered no significant evidence of widespread brain inflammation in individuals suffering from lingering symptoms after a COVID-19 infection. Instead, those experiencing more severe symptoms exhibited heightened activity in brain areas associated with emotion, stress, and memory.
For a while now, long COVID has been thought to stem from ongoing brain inflammation triggered by SARS-CoV-2. Scientists have looked into this as a potential explanation for symptoms like fatigue, brain fog, anxiety, and depression. Yet, solid evidence has been limited.
To dig deeper, a team from the University of Turku in Finland utilized advanced brain imaging methods to assess individuals with long COVID who still had symptoms long after their initial infection.
“We did not observe evidence of widespread brain inflammation in patients with long COVID when compared to healthy controls,” stated Professor of Neuroimmunology and leader of the InFLAMES Research Flagship group, Laura Airas, who directed the study.
Examining Long COVID Patients Against Healthy Controls and MS Patients
The research involved 14 long COVID patients, 11 healthy volunteers, and 13 individuals with multiple sclerosis (MS), which is known for brain inflammation.
All participants underwent PET scans to detect neuroinflammation, alongside MRI scans to assess brain structure and white matter changes. Researchers also analyzed blood samples for biological markers indicating neuron and supporting cell damage.
When comparing the long COVID group to MS patients, the former exhibited significantly lower inflammatory activity in the brain’s white matter. Additionally, there were no significant differences in markers related to brain inflammation or neurodegeneration when contrasting long COVID patients with healthy individuals.
Inflammation Might Decrease Over Time Post-Infection
Earlier neuropathological studies on severe acute COVID-19 have suggested clear indicators of brain inflammation. However, in this study, researchers found that participants scanned within 16 months post-infection displayed higher inflammatory activity compared to those who had been ill for a longer duration.
This observation lends credence to the idea that inflammation might be more profound in the early stages of the illness, gradually dissipating over time, as noted by Airas.
Another key insight from the study was that patients with elevated anxiety and depression, as well as lower quality of life, demonstrated increased cellular activity in the hippocampus and amygdala, brain regions crucial for memory and emotional regulation.
The findings imply that changes in these emotion-related brain areas could be linked to the severity of symptoms among some long COVID patients.
Implications for Future Long COVID Treatments
The researchers believe these results enhance our scientific understanding of long COVID, challenging the assumption that chronic brain inflammation is the primary reason behind persistent symptoms for every patient.
Rather, the evidence suggests a more nuanced condition where inflammatory changes may be most acute shortly after infection, lessening over time.
Long COVID continues to be a significant global health concern, impacting millions with symptoms that can linger for months or even years after the initial illness.
In light of the findings, researchers propose that some patients dealing with persistent symptoms might benefit more from therapies targeting stress management and emotional regulation, rather than solely focusing on reducing inflammation.
“This study underscores the necessity of further exploring the complex biological mechanisms at play in long COVID. Understanding these processes is crucial for formulating targeted treatments,” remarked Airas.
The findings of Airas and her team were published in the Journal of Neurology.
The InFLAMES Flagship is a collaboration between the University of Turku and Åbo Akademi University in Finland, aimed at merging immunology with related research fields to create new diagnostic tools and personalized medical treatments, as part of the Research Council of Finland’s Flagship Program.
